The current analysis found MRI screening in the DENSE trial detected invasive breast cancers about 6 years earlier than mammography. The calculation is based on first and second round invasive cancer detection rates. The 6 years is also consistent with the trial’s high false positive rate in the second round that used “prior” first round exams to estimate lesion growth over the 2 years between rounds. The “how much earlier” measure provides an additional means for comparing the relative performance of breast cancer screening modalities.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords